Aducanumab binding to Aβ1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core
Name
palani-et-al-2025-aducanumab-binding-to-aβ1-42-fibrils-alters-dynamics-of-the-n-terminal-tail-while-preserving-the.pdf
Description
Published version
Size
7.5 MB
Format
Adobe PDF
Checksum (MD5)
abd02864fe1d1aab7c6d37da7379ae3e
Author(s)
Palani, Ravi Shankar
Williams, Christopher G
Thacker, Dev
Silvers, Robert
Qian, Fang
Weinreb, Paul H
Mueller, Leonard J
Linse, Sara
Griffin, Robert G
Date Issued
December 22, 2025
Journal
Proceedings of the National Academy of Sciences
Publisher
Proceedings of the National Academy of Sciences
Citation
R.S. Palani,C.G. Williams,D. Thacker,R. Silvers,F. Qian,P.H. Weinreb,L.J. Mueller,S. Linse, & R.G. Griffin, Aducanumab binding to Aβ1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core, Proc. Natl. Acad. Sci. U.S.A. 122 (52) e2515673122.
Version
Final published version
Abstract
Aducanumab, a human IgG1 antibody with plaque-clearing effects and modest clinical benefit, binds selectively to aggregated Aβ via the N-terminal region. Yet, the molecular details of how the antibody engages Aβ1-42 fibrils remain unresolved. Using magic-angle spinning NMR, we show that binding of aducanumab preserves the overall architecture of the Aβ1-42 fibril core while inducing significant structural and dynamic perturbations in the N-terminal region. Antibody binding markedly reduces flexibility in this domain, with the appearance of side-chain resonances from residues D1, E3, and histidine (likely H6) in dipolar-based experiments. These side chains—previously observed in scalar-coupling spectra of the unbound state—indicate rigidification of residues that were dynamic. The interaction extends to S8 and Y10, indicating broader fibril engagement than the minimal epitope (residues 3 to 7) defined in fragment-based studies. Perturbations in the C-terminal segment (G37–A42) are consistent with its spatial proximity to the antibody-bound N termini of neighboring monomers. Cryo-TEM images reveal fibrils bundling in the presence of aducanumab, consistent with lateral association via antibody cross-linking, supporting a model where surface coating and steric hindrance suppress secondary nucleation. This mode of action restricts monomer access to catalytic sites on the fibril surface, resulting in partial inhibition (~threefold reduction) of secondary nucleation. The effect depends on high avidity and relatively high stoichiometry but is ultimately limited by antibody size relative to N-terminal spacing along the fibril. These findings provide atomic-level insights into aducanumab’s binding mode and supply a structural framework for understanding antibody-mediated fibril recognition and for guiding next-generation therapies targeting Aβ aggregates in Alzheimer’s disease.
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.2515673122
